..................................................
I will delete posts that are
solicitation from a pump site
or solicitation of us by salesmen
..................................................
$NEXCF at resistance $0.88
OTC/QB avg daily volume (low) 16k website hold x 100% sell filings and news 3/27/2020
$6 million in Revenues Period Ended December 31st 2019
$SHMP looking for a bottom $0.027
OTC/QB - made a ton of money the 1st run ($0.02)
Avg daily Volume 440k
Now looking for a bottom play re entry. A Game Changer stock.
Perfected clean "farming" of salt water shrimp and fish. Website float 300.64m
100% sell filings and news 3/18/20 a fire has destroyed the main building
Note:
We are adopting a policy
of barring and deleting paid humps and the like !!
I will delete any paid promo. They come here to make
some use of our casual stock sharing environment.
Good riddance.
Sign in the entrance window:
We will also delete any so-called market research
advertisement or any post fronting such off-site and
any off-site email sign-up or company solicitation.
< All foreign exchange stocks are welcome so long
as their exchange is clearly shown each posting.
A word to the wise:
"Stock picking is work".
"The stock market
is all about work."
"Just you and it "
We follow stocks with a low float < 100M
and stocks with an ultra low float < 30M.
But whatever is moving well, makes a1list.
Charts qualify that are looking up in some way:
on a moving average at resistance or support,
or with a staging formation such as a bull flag.
An upgrading Pr is great too.
The float shown is the highest number
from OTCMarkets-YahooFinance-WSJournal.
I use the highest of any two I look at.
Re: O/S Checked against SEC filings.
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...
Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...
Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...
A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Account Based Marketing Platforms: The Path Ahead Middleton, Massachusetts – In a significant report by QKS Group, the global Account Based Marketing Platform (ABM) Market is charting a positive trajectory, with a projected compound annual growth rate (CAGR) of 12.01% extending through 2030. This analysis provides businesses with critical insights to adeptly navigate...
Exciting Prospects for XenDex on the XRP Ledger The crypto landscape is buzzing with excitement as the XenDex project emerges as a noteworthy contender on the XRP Ledger. With only six days left in its presale, investors are urged to act fast and seize the opportunity to purchase $XDX tokens before they hit mainstream exchanges. Major platforms like Binance, Gate.io,...
Mowi's Exceptional Performance in the Seafood Market Mowi has recently revealed outstanding financial results, showcasing revenues of €1.39 billion and an operational profit of €112 million in the latest quarter. These figures reflect a remarkable achievement despite the low salmon prices and increased supply growth in the market. Record High Salmon Volumes During a...
Transformative Growth Stories in Emerging Industries The market has seen an impressive surge in small-cap energy stocks as companies across various sectors, including luxury food, next-gen biomaterials, and RNA therapeutics, announced optimistic updates. This enthusiasm is reshaping investor perceptions and laying the groundwork for robust market dynamics. Top Wealth...
Cloudflare Executive Stock Sale and Company Growth Recently, Thomas J. Seifert, the Chief Financial Officer of Cloudflare, Inc. (NYSE: NET), made headlines by selling a significant amount of his stock. In this notable transaction, Seifert sold 15,000 shares of Cloudflare's Class A Common Stock for over $1.1 million. This sale was made under a pre-arranged trading plan...